2-chloro-N-(2-methylquinolin-8-yl)benzamide | 876899-41-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-chloro-N-(2-methylquinolin-8-yl)benzamide
• CAS: 876899-41-1
• 化学式: C₁₇H₁₃ClN₂O
• mdl: MFCD03395102
• 分子量: 296.756
• InChiKey: DEIJUWMLXWEUAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloro-N-(2-methylquinolin-8-yl)benzamide 、 邻苯二胺 在 sulfur 作用下， 反应 12.0h， 以44%的产率得到N-(2-(1H-benzo[d]imidazol-2-yl)quinolin-8-yl)-2-chlorobenzamide
  参考文献：
  名称：

  Synthesis, characterization and ethylene oligomerization of nickel complexes bearing N-(2-(1H-benzo[d]imidazol-2-yl)quinolin-8-yl)benzamide derivatives

  摘要：

  合成并表征了一系列 N-(2-(1-R-1H-苯并[d]咪唑-2-基)喹啉-8-基)-2-R1-4-R2-苯甲酰胺衍生物（5-12）。这些化合物 5-11(5: R = H, R1 = H, R2 = H; 6: R = H, R1 = Cl, R2 = H; 7:R = H, R1 = H, R2 = Cl; 8: R = H, R1 = H, R2 = Br; 9: R = Me, R1 = H, R2 = H; 10: R = Et, R1 = H, R2 = H; 11: R = iPr, R1 = H, R2 = H。然而，二甲基化合物 12 与 NiCl2-6H2O 反应生成了络合物 14a。进一步研究证实，化合物 12 会水解成新的化合物 N-甲基-2-（1-甲基-1H-苯并[d]咪唑-2-基）喹啉-8-胺 14，替代合成证实了 14a 的形成机理。所有镍络合物都通过元素分析和光谱分析进行了表征，代表性化合物（12、5a 和 14a）的分子结构通过单晶 X 射线衍射进行了测定。这些镍（II）配合物在与 Et2AlCl 活化时，在乙烯低聚过程中表现出良好到较高的活性，最高可达 7.6 × 106g mol-1(Ni) h-1。反应条件和配体性质对镍配合物的催化性能有影响。

  DOI：

  10.1039/b822441b
• 作为产物：
  描述：

  8-氨基喹哪啶 、 2-氯苯甲酸 在 亚磷酸三苯酯 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 24.0h， 以86%的产率得到2-chloro-N-(2-methylquinolin-8-yl)benzamide
  参考文献：
  名称：

  Synthesis, characterization and ethylene oligomerization of nickel complexes bearing N-(2-(1H-benzo[d]imidazol-2-yl)quinolin-8-yl)benzamide derivatives

  摘要：

  合成并表征了一系列 N-(2-(1-R-1H-苯并[d]咪唑-2-基)喹啉-8-基)-2-R1-4-R2-苯甲酰胺衍生物（5-12）。这些化合物 5-11(5: R = H, R1 = H, R2 = H; 6: R = H, R1 = Cl, R2 = H; 7:R = H, R1 = H, R2 = Cl; 8: R = H, R1 = H, R2 = Br; 9: R = Me, R1 = H, R2 = H; 10: R = Et, R1 = H, R2 = H; 11: R = iPr, R1 = H, R2 = H。然而，二甲基化合物 12 与 NiCl2-6H2O 反应生成了络合物 14a。进一步研究证实，化合物 12 会水解成新的化合物 N-甲基-2-（1-甲基-1H-苯并[d]咪唑-2-基）喹啉-8-胺 14，替代合成证实了 14a 的形成机理。所有镍络合物都通过元素分析和光谱分析进行了表征，代表性化合物（12、5a 和 14a）的分子结构通过单晶 X 射线衍射进行了测定。这些镍（II）配合物在与 Et2AlCl 活化时，在乙烯低聚过程中表现出良好到较高的活性，最高可达 7.6 × 106g mol-1(Ni) h-1。反应条件和配体性质对镍配合物的催化性能有影响。

  DOI：

  10.1039/b822441b

文献信息

• [EN] QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES<br/>[FR] QUINOLÉINES ET LEUR UTILISATION POUR TRAITER LES MALADIES DUES AU STRESS DU RÉTICULUM ENDOPLASMIQUE
  申请人：CELLADON CORP

  公开号：WO2016032569A1

  公开（公告）日：2016-03-03

  Provided herein are quinolines, e.g., a compound of Formula (I) or (IB), pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caused disease. Also provided herein are methods of their use for reducing endoplasmic reticulum stress and modulating the activity of a sarcoplasmic/endoplasmic reticulum Ca2+ ATPase.

  本文提供了喹啉类化合物，例如，化合物的化学式为（I）或（IB），以及其药物组合物，并用于治疗、预防或改善内质网应激引起的一种或多种疾病症状的方法。本文还提供了用于减少内质网应激并调节肌浆/内质网Ca2+ ATP酶活性的方法。
• QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE
  申请人：Dahl Rusell

  公开号：US20190151303A1

  公开（公告）日：2019-05-23

  Provided herein are quinolines, e.g., a compound of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes. Also provided herein are methods of their use for modulating the activity of a sarcoplasmic/endoplasmic reticulum C 2+ ATPase.

  本文提供了喹啉，例如Formula I的化合物，其药物组合物，以及用于治疗、预防或缓解神经疾病、神经退行性疾病或糖尿病的一种或多种症状的方法。本文还提供了用于调节肌浆网/内质网C2+ATP酶活性的方法。
• Quinolines that modulate SERCA and their use for treating disease
  申请人：Dahl Russell

  公开号：US10772881B2

  公开（公告）日：2020-09-15

  Provided herein are quinolines, e.g., a compound of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes. Also provided herein are methods of their use for modulating the activity of a sarcoplasmic/endoplasmic reticulum C2+ ATPase.

  本文提供了喹啉类化合物，例如式 I 的化合物，其药物组合物，以及使用它们治疗、预防或改善神经系统疾病、神经退行性疾病或糖尿病的一种或多种症状的方法。本文还提供了它们用于调节肌浆/内质网 C2+ ATP 酶活性的方法。
• QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES
  申请人：EIGER BIOPHARMACEUTICALS, INC.

  公开号：US20170281611A1

  公开（公告）日：2017-10-05

  Provided herein are quinolines, e.g., a compound of Formula (I) or (IB), pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caused disease. Also provided herein are methods of their use for reducing endoplasmic reticulum stress and modulating the activity of a sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase.
• Synthesis, characterization and ethylene oligomerization of nickel complexes bearing N-(2-(1H-benzo[d]imidazol-2-yl)quinolin-8-yl)benzamide derivatives
  作者：Kefeng Wang、Miao Shen、Wen-Hua Sun

  DOI：10.1039/b822441b

  日期：——

  A series of N-(2-(1-R-1H-benzo[d]imidazol-2-yl)quinolin-8-yl)-2-R1-4-R2-benzamide derivatives (5–12) was synthesized and characterized. These compounds 5–11 (5: R = H, R1 = H, R2 = H; 6: R = H, R1 = Cl, R2 = H; 7:R = H, R1 = H, R2 = Cl; 8: R = H, R1 = H, R2 = Br; 9: R = Me, R1 = H, R2 = H; 10: R = Et, R1 = H, R2 = H; 11: R = iPr, R1 = H, R2 = H.) were treated with KOH, and then reacted with Ni(Ac)2·4H2O to form their nickel complexes (5a-11a), however, the dimethylated compound 12 reacted with NiCl2·6H2O to give complex 14a. Further investigation confirmed that compound 12 hydrolysized into a new compound N-methyl-2-(1-methyl-1H-benzo[d]imidazol-2-yl)quinolin-8-amine 14, and alternative synthesis confirmed the formation mechanism of 14a. All nickel complexes were characterized by elemental and spectroscopic analyses, and molecular structures of the representative compounds (12, 5a and 14a) were determined by the single-crystal X-ray diffraction. These Ni(II) complexes exhibited good to high activities up to 7.6 × 106g mol−1(Ni) h−1 in ethylene oligomerization upon activation with Et2AlCl. The reaction conditions and the nature of ligands affected on the catalytic performances of nickel complexes.

  合成并表征了一系列 N-(2-(1-R-1H-苯并[d]咪唑-2-基)喹啉-8-基)-2-R1-4-R2-苯甲酰胺衍生物（5-12）。这些化合物 5-11(5: R = H, R1 = H, R2 = H; 6: R = H, R1 = Cl, R2 = H; 7:R = H, R1 = H, R2 = Cl; 8: R = H, R1 = H, R2 = Br; 9: R = Me, R1 = H, R2 = H; 10: R = Et, R1 = H, R2 = H; 11: R = iPr, R1 = H, R2 = H。然而，二甲基化合物 12 与 NiCl2-6H2O 反应生成了络合物 14a。进一步研究证实，化合物 12 会水解成新的化合物 N-甲基-2-（1-甲基-1H-苯并[d]咪唑-2-基）喹啉-8-胺 14，替代合成证实了 14a 的形成机理。所有镍络合物都通过元素分析和光谱分析进行了表征，代表性化合物（12、5a 和 14a）的分子结构通过单晶 X 射线衍射进行了测定。这些镍（II）配合物在与 Et2AlCl 活化时，在乙烯低聚过程中表现出良好到较高的活性，最高可达 7.6 × 106g mol-1(Ni) h-1。反应条件和配体性质对镍配合物的催化性能有影响。